Category Archives: Patent Eligible Subject Matter

Solicitor General’s Vanda Brief Deconstructs Mayo

Posted on March 19, 2020 by Warren Woessner

When I was writing my post on INO Therapeutic’s Petition for Cert. on March 16th, I noticed the cite to the “invitation brief in Hikma Pharmaceuticals USA, Inc. v. Vanda Pharmaceuticals Inc., No. 18-817 (U.S. Dec. 6, 2019)(“the brief”). While … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , | Leave a comment

Illumina v. Ariosa – The “Bucket” to Be In

Posted on March 17, 2020 by Warren Woessner

Today, a divided Fed. Cir. panel reversed the district court’s decision invalidating the claim of two Illumina patents, U.S. Pat. Nos. 9,580,751 and 9,738,931, as directed to a natural phenomenon (Illumina, Inc. v. Ariosa Diagnostics, Inc., Appeal No. 2019-1419 (Fed. … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , | Leave a comment

INO v. Praxair – Time for the Supreme Court to Step Up to the Plate?

Posted on March 16, 2020 by Warren Woessner

Before you read this post, please back up and read my post of September 3, 2019 which discusses the Fed. Cir.’s ruling that the claims of U.S. Pat. No. 8,794,742 are patent-ineligible as attempts to claim a natural phenomenon. The … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , | Leave a comment

Solicitor General’s Briefs Encourage Supreme Court to Put s. 101 Back on Track

Posted on December 10, 2019 by Warren Woessner

Earlier this year, the Supreme Court issued orders to the Solicitor General to weigh in on whether or not the Court should grant cert. in two high profile Fed. Cir. decisions: Hikma Pharm. USA Inc, v. Vanda Pharm. Inc., No. … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , | Leave a comment